Scarica l'app Stockscreener
34.33
2.23%
0.75
Dopo l'orario di chiusura:
34.33
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Nuveen Asset Management LLC Cuts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Ameriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 | AGIO Stock News - GuruFocus
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - The Manila Times
Agios Pharmaceuticals Showcases Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
BNP Paribas Financial Markets Sells 2,242 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is Zacks Research’s Estimate for AGIO Q2 Earnings? - Defense World
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook By Investing.com - Investing.com South Africa
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook - Investing.com Canada
Bank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Sell Rating by StockNews.com - Defense World
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Update Their Estimates For Agios Pharmaceuticals Inc - Stocksregister
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities - The Globe and Mail
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Sickle cell disease Market: Epidemiology, Therapies, - openPR.com
Agios Pharmaceuticals at Bank of America 2025 Healthcare Conference: Strategic Pipeline Advances - Investing.com Canada
Agios to Highlight Pyruvate Kinase Activation Portfolio with New - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 20 - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 2025 | AGIO Stock News - GuruFocus
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - The Manila Times
New Phase 3 Trial Data: Agios Blood Disorder Treatment Shows Promise in Children and Adults with Rare Diseases - Stock Titan
Northern Trust Corp Purchases 5,372 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Relapsed or Refractory Myelodysplastic Syndrome Pipeline - openPR.com
Cantor Fitzgerald maintains AGIOS stock with Overweight rating By Investing.com - Investing.com Canada
Top-line data from Phase 3 trial of mitapivat expected this year - Sickle Cell Disease News
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.00 - Defense World
Trading (AGIO) With Integrated Risk Controls - news.stocktradersdaily.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.com - Defense World
Agios to Present at the 2025 RBC Capital Markets Global Healthca - GuruFocus
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire
Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com
Scotiabank Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - Defense World
Envestnet Asset Management Inc. Boosts Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank Analyst | AGIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
AGIO Receives Price Target Adjustment from Scotiabank | AGIO Stock News - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus
Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com
0.00%
2.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):